Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Neighbourly Pharmacy Inc T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or... see more

TSX:NBLY - Post Discussion

Neighbourly Pharmacy Inc > BMO comment
View:
Post by incomedreamer11 on Aug 03, 2022 3:18pm

BMO comment

 

BMO Capital's Take on Neighbourly Pharmacy's Q1 Results, from 1 hour ago by MT Newswires

1 hour ago by MT Newswires
 

01:57 PM EDT, 08/03/2022 (MT Newswires) -- BMO Capital writes that with Neighbourly Pharmacy's Q1 2023 results, a number of disappointing developments surfaced -- a lackluster pharmacy same-store-sales growth of 1.8% vs. Shoppers Drug Mart's pharmacy (ex. front-store) SSS of 6.1%; lower-than-expected projection of 15 acquisitions for the balance of FY2023E; and increased costs for filling pharmacist vacancies to persist for another year.

"Although the stock has fallen to ~14x F2023E EBITDA, and is in line with historical multiples for Shoppers and Jean Coutu, we expect NBLY will remain at these levels in the near term."

BMO has a Market Perform and US$22.50 target on the company.

Price: 20.91, Change: -0.22, Percent Change: -1.04

BMO Capital's Take on Neighbourly Pharmacy's Q1 Results, from 1 hour ago by MT Newswires

1 hour ago by MT Newswires
 

01:57 PM EDT, 08/03/2022 (MT Newswires) -- BMO Capital writes that with Neighbourly Pharmacy's Q1 2023 results, a number of disappointing developments surfaced -- a lackluster pharmacy same-store-sales growth of 1.8% vs. Shoppers Drug Mart's pharmacy (ex. front-store) SSS of 6.1%; lower-than-expected projection of 15 acquisitions for the balance of FY2023E; and increased costs for filling pharmacist vacancies to persist for another year.

"Although the stock has fallen to ~14x F2023E EBITDA, and is in line with historical multiples for Shoppers and Jean Coutu, we expect NBLY will remain at these levels in the near term."

BMO has a Market Perform and US$22.50 target on the company.

Price: 20.91, Change: -0.22, Percent Change: -1.04

Be the first to comment on this post